# Changes in bone characteristics precede serum mineral deterioration in a mouse model of early stage chronic kidney disease

**Authors:** Lieve Verlinden, Ingrid Stockmans, Karen Moermans, Geert Carmeliet

PMC · DOI: 10.1093/jbmrpl/ziag017 · JBMR Plus · 2026-02-02

## TL;DR

In a mouse model of early chronic kidney disease, bone changes occur before serum mineral levels are affected, showing early signs of bone deterioration.

## Contribution

This study reveals that bone formation declines and bone marrow adiposity increases before serum calcium levels change in early CKD.

## Key findings

- Bone mass decreases in trabecular and later cortical bone in Col4a3−/− mice.
- Osteoblast number and activity are reduced, while osteoclast numbers remain unchanged.
- Increased bone marrow adiposity is associated with reduced bone formation in early CKD.

## Abstract

Calcium metabolism is tightly regulated and involves hormonal communication between the intestine, kidney, and bone. Renal failure leads to impaired calcium homeostasis, but how each of the calcium-handling tissues adapts during the initial phases of the disease, remains to be explored. To this end, we used Col4a3−/− mice in which CKD develops progressively, as shown by the gradually decreased glomerular filtration rate and increased uremia. Mineral homeostasis was disturbed with increased serum levels of phosphaturic hormones, FGF23, and PTH and decreased 1,25(OH)2D3 levels. These hormonal adaptations in Col4a3−/− mice preserved normal serum calcium levels and maintained intestinal calcium absorption and renal fractional clearance of calcium. However, bone mass was already affected, starting with a decrease in trabecular bone mass and later evolving to additional cortical bone loss. Histomorphometric analysis of Col4a3−/− mice revealed a reduced osteoblast number and activity, whereas osteoclast numbers were not different. Interestingly, the decrease in bone formation was associated with an increase in BM adiposity. Taken together, we show that the renal impairment in Col4a3−/− mice leads to the typical hormonal alterations of CKD that preserve normal serum calcium levels at the early stage, but the renal dysfunction already negatively affects bone formation and increases BM adiposity.

Graphical Abstract

## Linked entities

- **Genes:** COL4A3 (collagen type IV alpha 3 chain) [NCBI Gene 1285]
- **Chemicals:** 1,25(OH)2D3 (PubChem CID 5280453)
- **Diseases:** chronic kidney disease (MONDO:0005300)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Hprt1 (hypoxanthine phosphoribosyltransferase 1) [NCBI Gene 15452] {aka HPGRT, Hprt}, Pth (parathyroid hormone) [NCBI Gene 19226] {aka Pthp}, Fasn (fatty acid synthase) [NCBI Gene 14104] {aka A630082H08Rik, FAS}, Ctsk (cathepsin K) [NCBI Gene 13038] {aka MMS10-Q, Ms10q, catK}, Enpp1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) [NCBI Gene 18605] {aka 4833416E15Rik, CD203c, E-NPP 1, E-NPP1, Ly-41, M6S1}, Cyp27b1 (cytochrome P450, family 27, subfamily b, polypeptide 1) [NCBI Gene 13115] {aka Cp2b, Cyp1, Cyp27b, Cyp40, P450c1, Pddr}, Spp1 (secreted phosphoprotein 1) [NCBI Gene 20750] {aka 2AR, Apl-1, BNSP, BSPI, Bsp, ETA-1}, Bglap2 (bone gamma-carboxyglutamate protein 2) [NCBI Gene 12097] {aka BGP2, Bglap1, Bgp, Og2, mOC-B}, Vdr (vitamin D (1,25-dihydroxyvitamin D3) receptor) [NCBI Gene 22337] {aka Nr1i1}, Acp5 (acid phosphatase 5, tartrate resistant) [NCBI Gene 11433] {aka TRACP, TRAP}, Alpl (alkaline phosphatase, liver/bone/kidney) [NCBI Gene 11647] {aka ALP, APTNAP, Akp-2, Akp2, TNAP, TNSALP}, S100g (S100 calcium binding protein G) [NCBI Gene 12309] {aka CABP1, CaBP-D9K, Cabp9k, Calb3}, Slc8a1 (solute carrier family 8 (sodium/calcium exchanger), member 1) [NCBI Gene 20541] {aka D930008O12Rik, Ncx1}, Atp2b1 (ATPase, Ca++ transporting, plasma membrane 1) [NCBI Gene 67972] {aka 2810442I22Rik, E130111D10Rik, Pmca1}, Cyp24a1 (cytochrome P450, family 24, subfamily a, polypeptide 1) [NCBI Gene 13081] {aka 24-OHase, CP24, Cyp24}, Tnfsf11 (tumor necrosis factor (ligand) superfamily, member 11) [NCBI Gene 21943] {aka Ly109l, ODF, OPGL, RANKL, Trance}, Trpv5 (transient receptor potential cation channel, subfamily V, member 5) [NCBI Gene 194352] {aka CAT2, D630033B11, ECAC1}, FGF23 (fibroblast growth factor 23) [NCBI Gene 8074] {aka ADHR, FGFN, HFTC2, HPDR2, HYPF, PHPTC}, PTH (parathyroid hormone) [NCBI Gene 5741] {aka FIH1, PTH1}, Tnfrsf11b (tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)) [NCBI Gene 18383] {aka OCIF, Opg, TR1}, Col4a3 (collagen, type IV, alpha 3) [NCBI Gene 12828] {aka [a]3(IV), alpha3(IV)}, Fgf23 (fibroblast growth factor 23) [NCBI Gene 64654] {aka Fgf8b}, Kl (klotho) [NCBI Gene 16591] {aka alpha-kl}, Cldn12 (claudin 12) [NCBI Gene 64945], Lpar1 (lysophosphatidic acid receptor 1) [NCBI Gene 14745] {aka Edg2, Gpcr26, Kdt2, lpA1, vzg-1}, Slc34a1 (solute carrier family 34 (sodium phosphate), member 1) [NCBI Gene 20505] {aka NaPi-IIa, Npt2, Npt2a, Slc17a2}, Cldn2 (claudin 2) [NCBI Gene 12738], Fabp4 (fatty acid binding protein 4, adipocyte) [NCBI Gene 11770] {aka 422/aP2, AFABP, ALBP, ALBP/Ap2, Ap2, Lbpl}, CYP27B1 (cytochrome P450 family 27 subfamily B member 1) [NCBI Gene 1594] {aka CP2B, CYP1, CYP1alpha, CYP27B, P450c1, PDDR}, Fgfr1 (fibroblast growth factor receptor 1) [NCBI Gene 14182] {aka Eask, FGFR-I, FLG, Fgfr-1, Flt-2, Fr1}, Pparg (peroxisome proliferator activated receptor gamma) [NCBI Gene 19016] {aka Nr1c3, PPAR-gamma, PPAR-gamma2, PPARgamma, PPARgamma2}, Adipoq (adiponectin, C1Q and collagen domain containing) [NCBI Gene 11450] {aka 30kDa, APN, Acdc, Acrp30, Ad, Adid}, Calb1 (calbindin 1) [NCBI Gene 12307] {aka Brain-2, CB, Calb, Calb-1}, Slc34a3 (solute carrier family 34 (sodium phosphate), member 3) [NCBI Gene 142681] {aka Npt2c, Npt2c-v1, NptIIc, naPi-2c}, Trpv6 (transient receptor potential cation channel, subfamily V, member 6) [NCBI Gene 64177] {aka CAT, CaT1, Cac, Ecac2, Otrpc3}, Plin1 (perilipin 1) [NCBI Gene 103968] {aka 6030432J05Rik, Peri, Plin}
- **Diseases:** adiposity (MESH:D018205), impairment of kidney function (MESH:D007674), impaired calcium (MESH:D002128), anorexia nervosa (MESH:D000856), Alport syndrome (MESH:D009394), hypocalcemia (MESH:D006996), calcium malabsorption (MESH:D008286), OsteoidS (MESH:D010017), CKD (MESH:D012080), cardiovascular complications (MESH:D002318), weight loss (MESH:D015431), ocular and auditory defects (MESH:D006311), bone defects (MESH:D001847), osteoporosis (MESH:D010024), dysregulation of mineral and bone metabolism (MESH:D001851), acute renal damage (MESH:D058186), uremia (MESH:D014511), renal fibrosis (MESH:D005355), fracture (MESH:D050723), Renal failure (MESH:D051437), calcifications (MESH:D002114), CKD (MESH:D051436)
- **Chemicals:** ATP (MESH:D000255), fructose (MESH:D005632), mannitol (MESH:D008353), CO2 (MESH:D002245), Paraformaldehyde (MESH:C003043), chloroform (MESH:D002725), calcein (MESH:C007740), PBS (MESH:D007854), 1,25(OH)2D3 (MESH:D002117), alcohol (MESH:D000438), FITC-inulin (MESH:C584353), glucose (MESH:D005947), creatinine (MESH:D003404), Ca (MESH:D002118), 25OHD (-), Alizarin (MESH:C010078), H&amp;E (MESH:D006371), HEPES (MESH:D006531), penicillin (MESH:D010406), dexamethasone (MESH:D003907), indomethacin (MESH:D007213), 3-isobutyl-1-methylxanthine (MESH:D015056), urea (MESH:D014508), bicarbonate (MESH:D001639), phenol (MESH:D019800), water (MESH:D014867), Oil Red O (MESH:C011049), TRIzol (MESH:C411644), CaCl2 (MESH:D002122), alphaMEM (MESH:C420642), Inulin (MESH:D007444), HCl (MESH:D006851), adenine (MESH:D000225), ascorbic acid (MESH:D001205), LPA (MESH:C032881), paraffin (MESH:D010232), NaCl (MESH:D012965), vitamin D (MESH:D014807), inorganic phosphate (MESH:D010710), Pi (MESH:D010716), nitrogen (MESH:D009584), EDTA (MESH:D004492), triglycerides (MESH:D014280), streptomycin (MESH:D013307)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** I013518N

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12954395/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12954395/full.md

## References

58 references — full list in the complete paper: https://tomesphere.com/paper/PMC12954395/full.md

---
Source: https://tomesphere.com/paper/PMC12954395